The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota
Clostridioides difficile is the most prevalent pathogen of nosocomial diarrhea. In the United States, over 450,000 cases of C. difficile infection (CDI), responsible for more than 29,000 deaths, are reported annually in recent years. Because of the emergence of hypervirulent strains and strains less...
Saved in:
| Main Authors: | Yongrong Zhang, Ashley Saint Fleur, Hanping Feng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2022.2052698 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clostridioides difficile concentration-dependant alterations in gut microbiota of asymptomatic infants
by: Aleksander Mahnic, et al.
Published: (2025-04-01) -
Gut Microbiota Composition and Clostridioides Difficile Infection: The Potential Protective Role of Faecalibacterium Prausnitzii
by: Nadim Cassir, et al.
Published: (2024-12-01) -
Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection
by: Josh Claypool, et al.
Published: (2025-12-01) -
Caffeic acid phenethyl ester protects Clostridioides difficile infection by toxin inhibition and microbiota modulation
by: Yan Guo, et al.
Published: (2025-06-01) -
Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection
by: Shaodong Wei, et al.
Published: (2022-12-01)